Daniel Morgensztern MD

Assistant Professor of Medicine (Medical Oncology)

Lung cancer; targeted therapy; molecular diagnosis; prognosis; supportive care; epidemiology; head and neck cancer

Morgensztern D, Ng SH, Gao F, Govindan R. Trends in stage distribution for patients with non-small cell lung cancer: A national cancer database survey. J Thorac Oncol 2010; 5: 29-33.
Morgensztern D, Waqar S, Subramanian J, Gao F, Govindan R. Improving survival for stage IV non-small cell lung cancer: A Surveillance, Epidemiology, and End Results survey from 1990 to 2005. J Thorac Oncol 2009, 4: 1524-1529.
Morgensztern D, Goodgame B, Baggstrom MQ, Gao F, Govindan R. The effect of FDG-PET scan on non-small cell lung cancer stage distribution. J Thorac Oncol 2008; 3: 135-139.
Morgensztern D, Govindan R. Adjuvant chemotherapy for lung cancer: cisplatin doublets only? J Natl Compr Cancer Netw 2008; 6: 277-284.
Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006; 24: 4539-4544.
Morgensztern D, McLeod HL. The PI3K/Akt/mTOR pathway as a target for cancer therapy. Anti-cancer drugs 2005; 16: 797-803.